Global Cancer Cachexia Therapeutics Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Cancer Cachexia Therapeutics Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

The cachexia of cancer patients has attracted the attention of the medical community. Cachexia is a secondary reaction due to metabolic disorders, manifested as extreme weight loss, skinny, skeleton-like, anemia, weakness, completely bedridden, unable to take care of itself, extreme pain, and general failure and other syndromes. Mostly caused by cancer and other serious chronic diseases. It can be regarded as a state of intoxication caused by many organs in the body. Some drugs such as corticosteroids and progestational drugs have obvious effects on promoting appetite, increasing food intake and improving mood; combination therapies and other methods are also used to improve the quality of life of cancer patients. However, it is worth noting that there is currently insufficient evidence to strongly support any drug to improve the outcome of cancer cachexia, and in fact, that there is currently no drug approved by the US Food and Drug Administration (FDA) for cancer cachexia.

Market Overview:

The latest research study on the global Cancer Cachexia Therapeutics market finds that the global Cancer Cachexia Therapeutics market reached a value of USD 6.85 million in 2022. It’s expected that the market will achieve USD 38.97 million by 2028, exhibiting a CAGR of 33.61% during the forecast period.

At the beginning of an outbreak, work is usually delayed and the normal production of the company is affected. For companies in some areas where the epidemic is relatively mild and can start operations normally, even if they start operations at normal times, they will face insufficient supply of raw materials, resulting in lower than normal capacity utilization. The spread of epidemics caused by transportation affects normal cargo transportation. According to data, the incubation period of the new coronavirus that caused this epidemic is about 7-14 days. In many countries, there are many cases of transmission in long-distance buses, trains, airplanes and other transportation vehicles. Therefore, areas with more severe epidemics have taken certain measures to control transportation. As an important exporter of APIs, Xin Guobing, China Deputy Minister of Industry and Information Technology, said that in January and February this year, due to the impact of the epidemic, some companies in China stopped work and production, and there was a short-term supply shortage. After February, due to the spread of the international epidemic, international transportation, especially shipping and sea transportation, has been greatly restricted and affected, resulting in some logistics and transportation problems, and transportation difficulties; the export volume of APIs compared with the same period last year There has been a decline. Most products have fallen by 10% to 20%, and individual varieties have fallen by 30%.

The epidemic also forced the government, experts, and pharmaceutical companies to focus on epidemic-related drugs, and the demand for non-anti-epidemic medical treatment has been suspended. Non-anti-epidemic medical needs may have a short-term outbreak after the resumption of work and production, but the risk is that the epidemic may still break out for a second time, which will affect the transportation of raw materials, production, and non-protest medical needs. Therefore, even if the final impact depends on the development of the epidemic, some losses have been caused.

Region Overview:

In 2022, the share of the Cancer Cachexia Therapeutics market in North America stood at 89.87%.

Segmentation Overview:

Progestogens

Progesterone is a steroid hormone that binds and activates the progesterone receptor (PR). In addition to its role as a natural hormone, progesterone is also used as a medicine. In the treatment of cancer cachexia, Megestrol can treat CACS by increasing appetite and weight gain. However, according to reports, progesterone may have potentially serious side effects and does not improve the quality of life compared with other treatments.

Corticosteroids

Corticosteroids are a class of drugs that reduce inflammation in the body. They also reduce the activity of the immune system. Because corticosteroids can relieve swelling and allergic reactions, increase appetite, and reduce fatigue, they can be used for many diseases. For example, dexamethasone can be used for the treatment of cancer cachexia.

Combination Therapies

Combination therapy is the use of more than one drug or method of treatment. Since cancer cachexia is defined as a multifactor syndrome, an effective treatment method may be a comprehensive and multifaceted treatment for different pathophysiological mechanisms at the same time.

Key Companies in the global Cancer Cachexia Therapeutics market covered in Chapter 3:

Teva Pharmaceutical Industries Ltd.
ANI Pharmaceuticals Inc.
Bristol-Myers Squibb Co.
Sun Pharmaceutical Industries Ltd.
Fresenius SE and Co. KGaA
Mylan NV
Hikma Pharmaceuticals Plc.
AbbVie Inc.
Pfizer Inc.
Merck and Co. Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the Cancer Cachexia Therapeutics market from 2018 to 2029 is primarily split into:

Progestogens
Corticosteroids
Combination Therapies
Other Therapeutics

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Cancer Cachexia Therapeutics market from 2018 to 2029 covers:

Hospital Stores
Retail Pharmacy Stores
Online Pharmacy

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)